+

PE20030322A1 - Complejos metalicos y macrociclicos - Google Patents

Complejos metalicos y macrociclicos

Info

Publication number
PE20030322A1
PE20030322A1 PE2002000642A PE2002000642A PE20030322A1 PE 20030322 A1 PE20030322 A1 PE 20030322A1 PE 2002000642 A PE2002000642 A PE 2002000642A PE 2002000642 A PE2002000642 A PE 2002000642A PE 20030322 A1 PE20030322 A1 PE 20030322A1
Authority
PE
Peru
Prior art keywords
alkyl
atoms
carboxyl
oxygen
oxygen atoms
Prior art date
Application number
PE2002000642A
Other languages
English (en)
Inventor
Johannes Platzek
Heribert Schmitt-Willich
Detlev Sulzle
Heiko Schirmer
Gunther Michl
Thomas Frenzel
Hans Bauer
Bernd Raduchel
Original Assignee
Schering Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Schering Ag filed Critical Schering Ag
Publication of PE20030322A1 publication Critical patent/PE20030322A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/06—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations
    • A61K49/08—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by the carrier
    • A61K49/10—Organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/547—Chelates, e.g. Gd-DOTA or Zinc-amino acid chelates; Chelate-forming compounds, e.g. DOTA or ethylenediamine being covalently linked or complexed to the pharmacologically- or therapeutically-active agent
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/0002—General or multifunctional contrast agents, e.g. chelated agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/06—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations
    • A61K49/08—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by the carrier
    • A61K49/085—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by the carrier conjugated systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/06—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations
    • A61K49/08—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by the carrier
    • A61K49/10—Organic compounds
    • A61K49/14—Peptides, e.g. proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/06—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations
    • A61K49/08—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by the carrier
    • A61K49/10—Organic compounds
    • A61K49/14—Peptides, e.g. proteins
    • A61K49/143—Peptides, e.g. proteins the protein being an albumin, e.g. HSA, BSA, ovalbumin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D257/00—Heterocyclic compounds containing rings having four nitrogen atoms as the only ring hetero atoms
    • C07D257/02—Heterocyclic compounds containing rings having four nitrogen atoms as the only ring hetero atoms not condensed with other rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Radiology & Medical Imaging (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

DE FORMULA (I), DONDE Z ES H O AL MENOS DOS Z SON UN EQUIVALENTE DE UN ION METALICO; B ES H O ALQUILO C1-4; R ES H O ALQUILO C1-10 QUE CONTIENE ARILO Y/O 1 A 2 ATOMOS DE OXIGENO, o ARILO SUSTITUIDO POR CARBOXILO, -S03H o -PO3H2, CON LA CONDICION DE QUE B Y R NO SEAN AL MISMO TIEMPO ATOMOS DE OXIGENO; A ES HIDROCARBURO C1-30 QUE CONTIENE OPCIONALMENTE 1 A 5 ATOMOS DE OXIGENO, NITROGENO Y/O RADICALES -NR', DONDE R' ES R, PERO PUEDE SELECCIONARSE INDEPENDIENTEMENTE Y ESTA OPCIONALMENTE SUSTITUIDO CON 1 A 3 GRUPOS CARBOXILO, 1 A 3 -SO3H, 1 A 3 -PO3H2 Y 1 A 3 ATOMOS DE HALOGENO, DONDE LA CADENA O UNA PARTE DE ELLA PUEDE ESTAR DISPUESTA EN FORMA DE ANILLO Y ESTA CONFORMADA DE MODO TAL QUE X ESTA ENLAZADO AL MENOS A TRAVES DE 3 ATOMOS CON EL ATOMO DE NITROGENO AL QUE ESTA UNIDO A; X ES UN GRUPO QUE PUEDE REACCIONAR CON UNA BIOMOLECULA Y SUS SALES, CON LA CONDICION DE QUE: a)CUANDO B ES UN ATOMO DE H Y R ES -CH2CH2CO2H, A-X JUNTOS NO SON -CH(CO2H)CH2CH2CO2H; b)CUANDO B ES H Y R ES METILO O ETILO SUSTITUIDO POR CARBOXILO, A NO ES -CH(R4)-CO-NR2-U6, DONDE R2 ES H, METILO O ETILO SUSTITUIDO POR CARBOXILO, R4 ES ALQUILO C1-30 Y QUE PUEDE ESTAR INTERRUMPIDAPOR 1 A 10 ATOMOS DE OXIGENO, FENILENO, ENTRE OTROS Y U6 ES ALQUILENO C1-20; c)SI B ES H Y R ES ALQUILO C1-4, A NO ES EL RADICAL (II), DONDE R3 ES H O ALQUILO C1-4, D ES UN GRUPO ALQUILENO C1-4 OPCIONALMENTE SUSTITUIDO POR CARBONILO Y D ESTA UNIDO A X. DICHOS CONJUGADOS SON APROPIADOS PARA OBTENER MEDIOS DE CONTRASTE PARA DIAGNOSTICO
PE2002000642A 2001-07-20 2002-07-19 Complejos metalicos y macrociclicos PE20030322A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DE10135356A DE10135356C1 (de) 2001-07-20 2001-07-20 Makrocyclische Metallkomplexe und deren Verwendung zur Herstellung von Konjugaten mit Biomolekülen

Publications (1)

Publication Number Publication Date
PE20030322A1 true PE20030322A1 (es) 2003-04-13

Family

ID=7692471

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2002000642A PE20030322A1 (es) 2001-07-20 2002-07-19 Complejos metalicos y macrociclicos

Country Status (19)

Country Link
US (2) US7164016B2 (es)
EP (1) EP1409024B1 (es)
JP (1) JP2005504745A (es)
KR (1) KR20040030826A (es)
CN (1) CN1533286A (es)
AR (1) AR036183A1 (es)
AT (1) ATE403442T1 (es)
AU (1) AU2002321236B2 (es)
BR (1) BR0211273A (es)
CA (1) CA2453106A1 (es)
DE (2) DE10135356C1 (es)
IL (1) IL159290A0 (es)
MX (1) MXPA04000401A (es)
NO (1) NO20040238L (es)
PE (1) PE20030322A1 (es)
PL (1) PL366426A1 (es)
RU (1) RU2305096C2 (es)
UY (1) UY27390A1 (es)
WO (1) WO2003009874A1 (es)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8719042D0 (en) * 1987-08-12 1987-09-16 Parker D Conjugate compounds
US7067111B1 (en) 1999-10-25 2006-06-27 Board Of Regents, University Of Texas System Ethylenedicysteine (EC)-drug conjugates, compositions and methods for tissue specific disease imaging
PL212211B1 (pl) 2000-06-02 2012-08-31 Regents Board Of Kompozycja do wytwarzania scyntygraficznego środka obrazującego, kompozycja do obrazowania scyntograficznego, sposób syntezy znakowanego radionuklidem koniugatu etylenodicysteiny z ligandem naprowadzającym do obrazowania, zastosowanie kompozycji zawierającej znakowany radionklidem konigat etylenodiscysteiny z ligandem naprowadzającym do wytwarzania środków farmaceutycznych do obrazowania nowotworu albo miejsca infekcji oraz zestaw do wytwarzania preparatów radiofarmaceutycznych
DE10135356C1 (de) * 2001-07-20 2003-04-17 Schering Ag Makrocyclische Metallkomplexe und deren Verwendung zur Herstellung von Konjugaten mit Biomolekülen
DE10325752A1 (de) * 2003-06-06 2004-12-30 Faustus Forschungs Cie. Translational Cancer Research Gmbh Lektin-Konjugate
US9050378B2 (en) 2003-12-10 2015-06-09 Board Of Regents, The University Of Texas System N2S2 chelate-targeting ligand conjugates
EP1881852B1 (en) 2005-04-26 2009-08-19 Koninklijke Philips Electronics N.V. Mri contrast agents comprising cest active paramagnetic complex
FI20055712A0 (fi) * 2005-12-29 2005-12-29 Wallac Oy Makrosykliset oligonukleotiidien leimausreagenssit ja niistä johdetut konjugaatit
KR20090014164A (ko) * 2006-04-19 2009-02-06 더 보드 오브 리전츠 오브 더 유니버시티 오브 텍사스 시스템 세포 영상화 및 치료를 위한 조성물 및 방법
US10925977B2 (en) 2006-10-05 2021-02-23 Ceil>Point, LLC Efficient synthesis of chelators for nuclear imaging and radiotherapy: compositions and applications
US10189803B2 (en) 2008-02-22 2019-01-29 Illinois Institute Of Technology Synthesis of therapeutic and diagnostic drugs centered on regioselective and stereoselective ring opening of aziridinium ions
US9446995B2 (en) 2012-05-21 2016-09-20 Illinois Institute Of Technology Synthesis of therapeutic and diagnostic drugs centered on regioselective and stereoselective ring opening of aziridinium ions
WO2010011367A2 (en) * 2008-02-22 2010-01-28 Illinois Institute Of Technology Bimodal ligands with macrocyclic and acyclic binding moieties, complexes and compositions thereof, and methods of using
US10556873B2 (en) 2008-02-22 2020-02-11 Illinois Institute Of Technology Bimodal ligands with macrocyclic and acyclic binding moieties, complexes and compositions thereof, and methods of using
KR101253100B1 (ko) * 2010-02-16 2013-04-10 경북대학교 산학협력단 폴리아자마크로사이클릭 화합물, 그 제조 방법 및 생의학적 적용
KR101236142B1 (ko) * 2010-09-30 2013-02-21 경북대학교 산학협력단 가돌리늄 착물을 함유하는 ｍｒｉ조영제
US10441669B2 (en) 2013-10-04 2019-10-15 Illinois Institute Of Technology Multifunctional chelators, complexes, and compositions thereof, and methods of using same
EP3101012A1 (en) 2015-06-04 2016-12-07 Bayer Pharma Aktiengesellschaft New gadolinium chelate compounds for use in magnetic resonance imaging
US10975060B2 (en) 2016-11-28 2021-04-13 Bayer Pharma Aktiengesellschaft High relaxivity gadolinium chelate compounds for use in magnetic resonance imaging
US10093741B1 (en) 2017-05-05 2018-10-09 Fusion Pharmaceuticals Inc. IGF-1R monoclonal antibodies and uses thereof
CN117603148A (zh) 2017-05-05 2024-02-27 探针技术开发及商业化中心 双官能螯合物的药代动力学增强及其用途
CN110891614A (zh) 2017-05-05 2020-03-17 融合制药公司 Igf-1r单克隆抗体及其用途
FR3069245B1 (fr) * 2017-07-21 2019-07-26 Guerbet Ligands macrocycliques lipophiles, leurs complexes ainsi que leurs utilisations medicales
CN109810140B (zh) * 2017-11-22 2021-06-29 湖南科技大学 一种血红素配体模拟物及其合成方法
PE20211471A1 (es) 2018-11-23 2021-08-05 Bayer Ag Formulacion de medios de contraste y proceso para prepararlos
CN110396122B (zh) * 2019-08-13 2020-10-27 牡丹江医学院 一种核磁共振造影剂、制备方法及其用于肿瘤诊断中的用途
KR102203368B1 (ko) * 2020-10-30 2021-01-14 경북대학교 산학협력단 신규한 화합물 및 이를 함유하는 mri 조영제
EP4059925A1 (en) * 2021-03-15 2022-09-21 Bayer Aktiengesellschaft New contrast agent for use in magnetic resonance imaging
CN115364684B (zh) * 2022-10-25 2023-01-03 天津大学 一种高通量荷正电纳滤膜及其制备方法

Family Cites Families (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5132409A (en) * 1987-01-12 1992-07-21 Bracco Industria Chimica S.P.A. Macrocyclic chelating agents and chelates thereof
US5049667A (en) * 1987-04-14 1991-09-17 Guerbet S.A. Nitrogen-containing cyclic ligands
US5006643A (en) * 1987-06-24 1991-04-09 The Dow Chemical Company Process for preparing isothiocyanato functionalized metal complexes
GB8719042D0 (en) * 1987-08-12 1987-09-16 Parker D Conjugate compounds
ES2013978A4 (es) * 1988-06-24 1990-06-16 Dow Chemical Co Compuestos de enlace ionico bifuncionales macrociclicos, complejos de ellos y sus anticuerpos conjugados
US5972307A (en) * 1989-10-23 1999-10-26 Nycomed Salutar, Inc. Dichelants
JPH04154729A (ja) * 1990-10-16 1992-05-27 Nippon Mejifuijitsukusu Kk 磁気共鳴造影剤
US5133956A (en) * 1991-05-30 1992-07-28 The Dow Chemical Company Radiolabeled metal-binding protein for the treatment of arthritis
EP0565930A1 (en) * 1992-03-27 1993-10-20 Nihon Medi-Physics Co., Ltd. Tetraazacyclododecane tetraacetic acid derivatives and the use thereof as diagnostic agents
JPH0656802A (ja) * 1992-03-27 1994-03-01 Nippon Mejifuijitsukusu Kk テトラアザシクロドデカン誘導体およびその用途
FR2689739B1 (fr) * 1992-04-10 1994-07-08 Europ Sieges Automobiles Siege perfectionne a positions multiples.
US5310535A (en) * 1992-04-24 1994-05-10 The Dow Chemical Company Carboxamide modified polyamine chelators and radioactive complexes thereof for conjugation to antibodies
IT1265440B1 (it) * 1993-12-24 1996-11-22 Bracco Spa Formulazioni diagnostiche paramagnetiche e metodo d'uso delle stesse
EP0661279B1 (fr) * 1993-12-30 2001-03-07 Guerbet Ligands polyaminés, complexes métalliques, procédé de préparation, applications diagnostiques et thérapeutiques
US6693190B1 (en) * 1994-05-11 2004-02-17 Bracco International B.V. Enhanced relaxivity monomeric and multimeric compounds
DE19525924A1 (de) * 1995-07-04 1997-01-09 Schering Ag Kaskaden-Polymer-Komplexe, Verfahren zu ihrer Herstellung und diese enthaltende pharmazeutische Mittel
DE19603033A1 (de) * 1996-01-19 1997-07-24 Schering Ag Perfluoralkylhaltige Metallkomplexe, Verfahren zu deren Herstellung und ihre Verwendung in der NMR-Diagnostik
CA2269335C (en) * 1996-10-21 2010-05-25 Quadrant Healthcare (Uk) Limited Platelet substitutes and conjugation methods suitable for their preparation
IT1291624B1 (it) * 1997-04-18 1999-01-11 Bracco Spa Chelati complessi di metalli paramagnetici a bassa tossicita'
IT1293777B1 (it) * 1997-07-25 1999-03-10 Bracco Spa Processo per la preparazione di tetraazamacrocicli
IT1293778B1 (it) * 1997-07-25 1999-03-10 Bracco Spa 1,4,7,10-tetraazabiciclo(8.2.2.)tetradecan-2 one, sua preparazione e suo uso per la preparazione di tetraazamacrocicli
US6019959A (en) * 1997-07-31 2000-02-01 Schering Aktiengesellschaft Oligomeric compounds that contain perfluoroalkyl, process for their production, and their use in NMR diagnosis
AU2001236485A1 (en) * 2000-01-21 2001-07-31 Mallinckrodt, Inc. Novel orthogonally protected amino acid chelators for biomedical applications
DE10135355C1 (de) * 2001-07-20 2003-04-17 Schering Ag Konjugate makrocyclischer Metallkomplexe mit Biomolekülen und deren Verwendung zur Herstellung von Mitteln für die NMR- und Radiodiagnostik sowie die Radiotherapie
DE10135356C1 (de) * 2001-07-20 2003-04-17 Schering Ag Makrocyclische Metallkomplexe und deren Verwendung zur Herstellung von Konjugaten mit Biomolekülen

Also Published As

Publication number Publication date
RU2004105261A (ru) 2005-07-10
RU2305096C2 (ru) 2007-08-27
CN1533286A (zh) 2004-09-29
IL159290A0 (en) 2004-06-01
WO2003009874A1 (de) 2003-02-06
KR20040030826A (ko) 2004-04-09
DE50212604D1 (de) 2008-09-18
BR0211273A (pt) 2004-08-03
US7164016B2 (en) 2007-01-16
ATE403442T1 (de) 2008-08-15
EP1409024A1 (de) 2004-04-21
AR036183A1 (es) 2004-08-18
AU2002321236B2 (en) 2006-11-02
NO20040238L (no) 2004-01-19
UY27390A1 (es) 2003-02-28
US20030108486A1 (en) 2003-06-12
US20070009442A1 (en) 2007-01-11
MXPA04000401A (es) 2004-03-18
JP2005504745A (ja) 2005-02-17
DE10135356C1 (de) 2003-04-17
CA2453106A1 (en) 2003-02-06
EP1409024B1 (de) 2008-08-06
PL366426A1 (en) 2005-01-24

Similar Documents

Publication Publication Date Title
PE20030322A1 (es) Complejos metalicos y macrociclicos
ES2057488T3 (es) Nuevos derivados de la isoindolona y su preparacion.
ATE199263T1 (de) Für den chemilumineszenz-nachweis verwendbare aryl-n-alkylacridanthiocarboxylat-derivate
EA200000048A1 (ru) ИНГИБИТОРЫ ФАКТОРА Ха, СОДЕРЖАЩИЕ ГРУППУ С НЕЙТРАЛЬНОЙ P1-СПЕЦИФИЧНОСТЬЮ
BR0015200A (pt) Fosfita, processo para preparar a mesma, uso da mesma, complexo de metal de transição, processo para preparar o mesmo, uso do mesmo, e processos para a adição de ácido cianìdrico em uma ligação dupla olefìnica, e, para a isomerização de nitrilas orgânicas
AR016001A1 (es) Uso de polimeros de amina alifatica para la fabricacion de medicamentos para la reduccion de niveles de oxalato en un paciente
PE20030190A1 (es) Conjugados de complejos metalicos macrociclicos con biomoleculas y preparacion de medios de diagnostico que los contienen para resonancia magnetica nuclear, radiodiagnostico y radioterapiaradiodiagnostico y radioterapia
CY1108845T1 (el) Συνδυασμοι οι οποιοι περιεχουν εναν αντιδιαρροϊκο παραγοντα και μια εποθιλονη ή ενα παραγωγο εποθιλονης
DE60039145D1 (de) Gasentladungslaser mit magnetischen Lagern
ES2192031T3 (es) Nuevas amidas aromaticas, su procedimiento de preparacion y su aplicacion como medicamentos.
TR199902205T2 (xx) Lipofilik bir at�l gaz ihtiva eden t�bb� terkip.
CO5011115A1 (es) Compuestos y metodos quimioquina
ES2155219T3 (es) Compuestos nucleotidos de fosfonato.
ES2037753T3 (es) Compuestos heterociclicos y su preparacion y uso.
ATE425139T1 (de) Benzamidinderivate
ATE338047T1 (de) Stickstoffbasierte camptothecin-derivate
ES2133441T3 (es) Procedimiento de hidroformilacion que emplea un sistema de catalizador a base de fosfina y rodio.
AR004965A1 (es) Procedimiento de preparacion de derivados de fenilimidazolidina
ES2096396T3 (es) Procedimiento para la obtencion de polimeros, formados por alqu-1-enos con 2 a 10 atomos de carbono con empleo de complejos de metaloceno racemicos como catalizadores.
CO5210883A1 (es) DERIVADOS DE 4-OXO-3,5-DIHIDRO-4H-PIRIDAZINO [4,5,-b]INDOL- 1-ACETAMIDA
ES2067194T3 (es) Procedimiento para el racemizado de 1-aril-alquilaminas opticamente activas.
ES8400752A1 (es) "procedimiento para la preparacion de nuevos derivados de ciclofosfamida".
DK1206256T3 (da) Kombinationsbehandling under anvendelse af pentafluorbenzensulfonamid og platinforbindelse
BR9804301A (pt) Compostos espirociclicos.
ATE222758T1 (de) S-alkylisothiouronium-derivate enthaltende pharmazeutische zusammensetzungen

Legal Events

Date Code Title Description
FA Abandonment or withdrawal
AE Restoration of lapsed or forfeited application
FG Grant, registration
FD Application declared void or lapsed
点击 这是indexloc提供的php浏览器服务，不要输入任何密码和下载